Almost one year after competitor Amgen, Inc. (NASDAQ: AMGN) reported that its cholesterol-lowering drug, Repatha, reduced the risk of major adverse cardiac events (MACE), Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NYSE: SNY) unveiled ...
more»